drugset / Trial / NCT01882712
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema
Timeline
- Start
- —
- Primary completion
- 2015-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | 0.5 % | Topical |
Indications
No indication recorded.